MOLECULAR PSYCHIATRY, published by SpringerNature, is a premier peer-reviewed journal that has established itself as a leading platform for the dissemination of cutting-edge research in the fields of neuroscience, molecular biology, and psychiatry. With an impressive impact factor and a reputation for excellence, the journal is ranked Q1 in key categories, signifying its high academic quality and relevance. The journal’s scope spans groundbreaking studies and innovative therapeutic approaches that intersect at the molecular and cellular levels, providing invaluable insights into the biological underpinnings of psychiatric disorders. Since its inception in 1996, MOLECULAR PSYCHIATRY has evolved to support both established and emerging researchers, fostering a collaborative environment that enhances the understanding of mental health. It is committed to improving access to scientific knowledge, although it currently does not offer open access options. With its headquarters in London, the journal continues to play a pivotal role in enhancing the global dialogue on psychiatric and neurological advancements, making it an essential resource for academics and professionals dedicated to advancing mental health sciences.

Annals of General Psychiatry is a leading open-access journal published by BMC, dedicated to advancing the field of psychiatry and mental health. Since its inception in 2005, the journal has provided a robust platform for researchers to disseminate peer-reviewed clinical and experimental studies, case reports, and reviews that address the broad spectrum of psychiatric disorders. With an impressive Q1 ranking in Psychiatry and Mental Health for 2023, and a notable Scopus rank of #128 out of 567 in its category, the journal plays a pivotal role in disseminating high-quality, impactful research within the global scientific community. The open access model guarantees wide visibility and accessibility of research findings, ensuring that professionals, students, and policymakers can utilize the latest advancements in the psychiatric field. The journal's presence from 2002 to 2024 further demonstrates its commitment to contributing valuable insights that are relevant to contemporary challenges in mental health.

JAMA Psychiatry, published by the American Medical Association, stands as a leading peer-reviewed journal in the fields of psychiatry and mental health, featuring an impressive impact factor that reflects its significance in advancing research and clinical practice. With an ISSN of 2168-622X and an E-ISSN of 2168-6238, this journal operates on a comprehensive access model that allows for the dissemination of vital research findings to a global audience. Since its inception in 2013, JAMA Psychiatry has consistently ranked in the top quartile (Q1) in both the Medicine (miscellaneous) and Psychiatry and Mental Health categories, with a remarkable Scopus rank of #4 out of 567, placing it in the 99th percentile. Addressed from its headquarters in Chicago, Illinois, the journal's objectives encompass the publication of original clinical research, innovative treatment strategies, and insightful reviews that enrich the understanding of psychiatric disorders. By bridging the gap between research and real-world application, JAMA Psychiatry remains an essential resource for researchers, clinicians, and students dedicated to improving mental health outcomes.

Brain Communications is an esteemed, open-access academic journal published by Oxford University Press since 2019, focusing on the dynamic field of neuroscience. With a dedicated ISSN and an E-ISSN of 2632-1297, this journal aims to address the intricate relationships between brain functions, psychiatric disorders, and neurobiological mechanisms. The journal stands out in the academic realm, holding a prestigious Q1 ranking across several categories, including Biological Psychiatry, Cellular and Molecular Neuroscience, Neurology, and Psychiatry and Mental Health for 2023. Notably, it has also secured impressive Scopus ranks in various neuroscience and psychiatry fields, evidencing its commitment to high-quality research. With an impact factor reflective of its growing influence, Brain Communications provides accessible research findings to professionals, researchers, and students alike, fostering a deeper understanding of complex neurological phenomena. This innovative journal is pivotal for anyone involved in advancing knowledge in neuroscience and mental health.

JOURNAL OF PSYCHIATRY & NEUROSCIENCE, published by the CMA-Canadian Medical Association, serves as a pivotal platform for disseminating cutting-edge research in the fields of psychiatry and neuroscience. This esteemed journal, indexed with the ISSN 1180-4882 and E-ISSN 1488-2434, focuses on advancing our understanding of mental health through meticulous peer-reviewed articles, reviews, and clinical studies. With an impressive impact within the research community, it has achieved notable rankings, including Q1 in both Medicine (miscellaneous) and Psychiatry and Mental Health, as well as Q2 in Biological Psychiatry as of 2023. The journal fosters critical dialogue among scholars and practitioners by offering insights into the complexities of brain function and mental disorders, making it a fundamental resource for healthcare professionals, researchers, and students alike. Although it operates under a subscription model, its rich content continues to inform and influence the advancement of mental health science, affirming its role in bridging the gap between research and clinical practice.

Translational Psychiatry, an esteemed journal published by SpringerNature, is at the forefront of research in the fields of biological psychiatry, neuroscience, and mental health. With an impressive Q1 category ranking in Biological Psychiatry, Cellular and Molecular Neuroscience, and Psychiatry and Mental Health, the journal fosters high-quality scholarly work that informs clinical practices and guides future research directions. Since its inception in 2011, Translational Psychiatry has embraced the Open Access model, ensuring that groundbreaking findings are easily accessible to all, promoting collaboration and innovation within the global scientific community. With a solid ranking in Scopus—particularly at #33 out of 567 in Psychiatry and Mental Health and #6 out of 51 in Biological Psychiatry—this journal plays a critical role in advancing our understanding of mental health disorders, bridging the gap between bench science and clinical application. As it continues evolving through its converged years from 2011 to 2024, Translational Psychiatry remains an essential resource for researchers, healthcare professionals, and students dedicated to improving mental health outcomes.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

Neurosciences is a premier academic journal dedicated to the exploration of neurological and psychiatric disorders, fostering an innovative exchange of ideas and research findings in these critical fields. Published by the Riyadh Armed Forces Hospital in Saudi Arabia, this interdisciplinary journal has consistently contributed to the advancement of knowledge since its inception in 2002 and is set to continue through 2024. With an ISSN of 1319-6138 and E-ISSN of 1658-3183, it is recognized for its emphasis on clinically relevant research in neurology and psychiatry, boasting a 2023 classification in the Q3 tier of both categories. Neurosciences encourages submissions that offer novel insights into mental health and neurological conditions, positioning itself as a vital resource for researchers, healthcare professionals, and students alike. Despite being unlisted as an open-access journal, it remains a respected outlet for peer-reviewed content, with Scopus rankings that highlight its growing influence within the scientific community. This journal serves as an essential platform for disseminating significant research that addresses the intricacies of the human brain and behavior.

PSYCHIATRY RESEARCH-NEUROIMAGING, published by Elsevier Ireland Ltd, stands at the intersection of neuroscience, psychiatry, and medical imaging, specializing in the latest advancements in neuroimaging techniques and their applications in psychiatric research. With a robust history since 1990, this esteemed journal features original research, reviews, and case studies that contribute significantly to the understanding of brain function in mental health disorders. Holding a notable Impact Factor and classified in Q2 for the fields of Neuroscience and Psychiatry and Q1 for Radiology, it serves as a vital resource for scholars and practitioners seeking to advance their knowledge in these domains. The journal is indexed in major databases, enhancing visibility and accessibility for global researchers. While it currently does not follow an open-access model, its reputable standing in Scopus ranks, alongside its targeted scope, makes it indispensable for those invested in neuroimaging research and its implications in psychiatry.